ClinicalTrials.gg
Drug

Lutetium (¹⁷⁷Lu) vipivotide tetraxetan clinical trials

Also written 177Lu-PSMA-617, Lutetium Lu 177 Vipivotide Tetraxetan, Pluvicto and AAA617.

studies test it
50
open now
26
in phase 3
6
first study started
2016

How each study uses lutetium (¹⁷⁷Lu) vipivotide tetraxetan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the lutetium (¹⁷⁷Lu) vipivotide tetraxetan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Lutetium Lu 177-PSMA-617
3
[177Lu]Lu-PSMA-617
2
Lu177-PSMA-617
2
Lu-177 PSMA-617
2
Lutetium-177-PSMA-617
2

Brand

Pluvicto
11

Development codes

177Lu-PSMA-617
29
AAA617
7

Other names

Lutetium Lu 177 Vipivotide Tetraxetan
14
Lutetium (177Lu) vipivotide tetraxetan
3

Studies by the year they started

50 studies that test it; most in 2025 (12)

Studies that test lutetium (¹⁷⁷Lu) vipivotide tetraxetan, by start year
YearStudies
20161
20171
20183
20191
20203
20215
20223
20232
202411
202512
20268

By phase

A phase 1/2 study counts in both.

Phase 1
18
Phase 2
32
Phase 3
6
Phase 4
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 9 · Other 41

Novartis Pharmaceuticals (7) · Peter MacCallum Cancer Centre, Australia (3) · University of California, San Francisco (3) · Jonsson Comprehensive Cancer Center (3) · Memorial Sloan Kettering Cancer Center (2) · Dana-Farber Cancer Institute (2) · Weill Medical College of Cornell University (2) · Radboud University Medical Center (2)

Often tested with

Tested in the same studies.

Carboplatin (3) · Cabazitaxel (3) · Abiraterone Acetate (2) · Abiraterone (2) · Prednisone (2) · Gallium 68 PSMA-11 (1) · Ipilimumab (1) · Nivolumab (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 1 phase 3 study under way

Lutetium (¹⁷⁷Lu) vipivotide tetraxetan is the comparator. A study of two new drugs counts under both.

  • 1Darolutamide · ECOG-ACRIN Cancer Research Group · next primary completion Mar 2029
Reaching primary completion within a year · 12

Studies that test lutetium (¹⁷⁷Lu) vipivotide tetraxetan.

Studies

Open first, then newest update. How each study uses lutetium (¹⁷⁷Lu) vipivotide tetraxetan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 50

See all 50 studies that test lutetium (¹⁷⁷Lu) vipivotide tetraxetan →

Given beside what is tested · 10 — lutetium (¹⁷⁷Lu) vipivotide tetraxetan is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with lutetium (¹⁷⁷Lu) vipivotide tetraxetan

Codes

What other systems call lutetium (¹⁷⁷Lu) vipivotide tetraxetan · ClinicalTrials.gg INT000522

  • MeSH (NLM) C000610110lutetium (177Lu) vipivotide tetraxetanConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) G6UF363ECXLUTETIUM LU-177 VIPIVOTIDE TETRAXETANConfirmed FDA, NLM, Wikidata
  • RxNorm 2597053One source FDA
  • Wikidata Q111353661lutetium (¹⁷⁷Lu) vipivotide tetraxetanConfirmed FDA, NLM, Wikidata
  • DrugBank DB16778One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.